Merck + Co., Inc.

Merck Gmbh

Ronald W Ratcliffe

Burton G Christensen

Thomas N Salzmann

Robert R Wilkening

Timothy A Blizzard

William J Leanza

Kenneth J Wildonger

Frank P DiNinno

John C Chabala

Lovji D Cama

James V Heck

Wanying Sun

David H Shih

Sherman Tim Waddell

Ravindra N Guthikonda

Dongfang Meng

Helmut Kropp

David A Muthard

Jerry Dwain Morgan, Ii

Jeffrey N Clark

Dann LeRoy Parker

Daniel O Farrington

Raymond A Firestone

John Hannah

Kevin D Dykstra

Dann LeRoy Parker, Jr

Kothandaraman Shankaran

Michael J Szymonifka

Thomas N Salzman

Robert D Wilkening

Burton G Christenson

Mary F Woods

Sandra P Szumiloski

Linda J Ruswinkle

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Pagets disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

Estrogen receptor modulators

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

Selective estrogen receptor modulators

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynacomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

1,8-naphthosultamylmethyl carbapenem antibacterial compounds, compositions containing such compounds and methods treatment

Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment

9a-Azalides, and pharmaceutical compositions containing them, are useful in the treatment and prevention of bacterial respiratory and enteric infections in livestock animals, particularly in cattle and swine.

9a-azalides as veterinary antimicrobial agents

Carbapenem antibacterial compounds, compositions containing such compounds and method of treatment

The present invention relates to carbapenem antibacterial agents of formula I:

Compounds of formula I are disclosed. ##STR1## as well as pharmaceutically acceptable salts thereof. The naphthosultam is substituted with various substituent groups including at least one cationic group -A-Q-L-B. The carbapenems of the invention are effective against susceptible bacterial organisms, including methicillin resistant Staphylococcus aureus (MRSA), methicillin resistant Staphylococcus epidermidis (MRSE), and methicillin resistant coagulase negative Staphylococci (MRCNS).

Carbapenem antibacterial compounds, compositions containing such

8a-Azalides are useful in the treatment and prevention of bacterial respiratory and enteric infections in livestock animals, particularly in cattle and swine.

8a-azalides as veterinary antimicrobal agents

Compounds of formula I: ##STR1## as well as pharmaceutically acceptable salts thereof are disclosed. R.sup.2 is H and R.sup.3 is C1-3 alkyl, or R.sup.2 and R.sup.3 taken in combination represent C.sub.1-3 alkylidene. Pharmaceutical compositions and methods of treatment are also included. The compounds are useful against methicillin resistant staphylococci (MRSA).

Growing community of inventors

Matawan, NJ, United States of America

Ronald W Ratcliffe